VPI-2690B

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameVPI-2690B
Drug Alias NameVPI-2690B
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIntegrin antagonistsInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptorIntegrin
Therapy Area/IndicationsDiabetic Nephropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto Rico
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of North Carolina At Chapel Hill
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVascular Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsDiabetic Nephropathies

Other Information

ATC CodeN/A
Related LinksN/A